Abstract |
The chemotherapy of hematological cancers is challenged by its poor selectivity that leads to low therapeutic efficacy and pronounced adverse effects. Here, we report that doxorubicin encapsulated in lipoic acid-crosslinked hyaluronic acid nanoparticles (LACHA-DOX) mediate highly efficacious and targeted inhibition of human hematological cancers including LP-1 human multiple myeloma (MM) and AML-2 human acute myeloid leukemia xenografted in nude mice. LACHA-DOX had a size of ca. 183 nm and a DOX loading content of ca. 12.0 wt.%. MTT and flow cytometry assays showed that LACHA-DOX possessed a high targetability and antitumor activity toward CD44 receptor overexpressing LP-1 human MM cells and AML-2 human acute myeloid leukemia cells. The in vivo and ex vivo images revealed that LACHA-DOX achieved a significantly enhanced accumulation in LP-1 and AML-2 tumor xenografts. Notably, LACHA-DOX effectively suppressed LP-1 as well as AML-2 tumor growth and drastically increased mice survival rate as compared to control groups receiving free DOX or PBS. Histological analyses exhibited that LACHA-DOX caused little damage to the major organs like liver and heart. This study provides a proof-of-concept that lipoic acid-crosslinked hyaluronic acid nanoparticulate drugs may offer a more safe and effective treatment modality for CD44 positive hematological malignancies.
|
Authors | Yinan Zhong, Fenghua Meng, Chao Deng, Xinliang Mao, Zhiyuan Zhong |
Journal | Drug delivery
(Drug Deliv)
Vol. 24
Issue 1
Pg. 1482-1490
(Nov 2017)
ISSN: 1521-0464 [Electronic] England |
PMID | 28958164
(Publication Type: Journal Article)
|
Chemical References |
- Thioctic Acid
- Doxorubicin
- Hyaluronic Acid
|
Topics |
- Animals
- Cell Line, Tumor
- Doxorubicin
- Hematologic Neoplasms
- Humans
- Hyaluronic Acid
- Mice
- Mice, Nude
- Nanoparticles
- Thioctic Acid
|